Glaxo snaps up US vaccine maker Affinivax in £2.6bn deal

Affinivax is developing a vaccine to combat pneumococcal diseases which include pneumonia and meningitis as well as milder illnesses such as sinusitis.

Related Keywords

Switzerland ,Swiss ,Max Herrmann ,Emma Walmsley ,Steven Brugger ,Hal Barron ,Novartis ,Boston Based Affinivax ,Sierra Oncology ,Elliott Management ,Thisismoney ,Money ,Moneymarkets ,